JOP20240223A1 - معالجات سرطان باستخدام مثبطات prmt5 بالتعاون مع mta - Google Patents

معالجات سرطان باستخدام مثبطات prmt5 بالتعاون مع mta

Info

Publication number
JOP20240223A1
JOP20240223A1 JOJO/P/2024/0223A JOP20240223A JOP20240223A1 JO P20240223 A1 JOP20240223 A1 JO P20240223A1 JO P20240223 A JOP20240223 A JO P20240223A JO P20240223 A1 JOP20240223 A1 JO P20240223A1
Authority
JO
Jordan
Prior art keywords
mta
collaboration
cancer treatments
prmt5 inhibitors
prmt5
Prior art date
Application number
JOJO/P/2024/0223A
Other languages
Arabic (ar)
English (en)
Inventor
Brian Belmontes
Edward Lau Yue Chan
Katherine Slemmons
Jan Sun
Paul Hughes
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20240223A1 publication Critical patent/JOP20240223A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOJO/P/2024/0223A 2022-04-08 2024-10-06 معالجات سرطان باستخدام مثبطات prmt5 بالتعاون مع mta JOP20240223A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329010P 2022-04-08 2022-04-08
US202263345736P 2022-05-25 2022-05-25
PCT/US2023/017805 WO2023196545A1 (en) 2022-04-08 2023-04-07 Cancer treatments using mta-cooperative prmt5 inhibitors

Publications (1)

Publication Number Publication Date
JOP20240223A1 true JOP20240223A1 (ar) 2024-10-06

Family

ID=86328467

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0223A JOP20240223A1 (ar) 2022-04-08 2024-10-06 معالجات سرطان باستخدام مثبطات prmt5 بالتعاون مع mta

Country Status (14)

Country Link
US (1) US20250228861A1 (enExample)
EP (1) EP4504199A1 (enExample)
JP (1) JP2025511399A (enExample)
KR (1) KR20240169712A (enExample)
CN (1) CN119317435A (enExample)
AU (1) AU2023249277A1 (enExample)
CA (1) CA3255376A1 (enExample)
CL (1) CL2024003040A1 (enExample)
IL (1) IL315996A (enExample)
JO (1) JOP20240223A1 (enExample)
MX (1) MX2024012431A (enExample)
TW (1) TW202345844A (enExample)
WO (1) WO2023196545A1 (enExample)
ZA (1) ZA202407596B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用mta協作的prmt5抑制劑和mat2a抑制劑之癌症治療
KR20250121432A (ko) * 2022-12-21 2025-08-12 암젠 인크 Mta-협력 prmt5 저해제를 사용한 암 치료
IL327337A (en) * 2023-10-06 2026-05-01 Amgen Inc Cancer treatments using PRMT5 inhibitors in collaboration with MTA
WO2025092818A1 (zh) * 2023-10-31 2025-05-08 康百达(四川)生物医药科技有限公司 一种吡啶衍生物及其在医药上的应用
CN121889382A (zh) * 2023-11-08 2026-04-17 北京泰德制药股份有限公司 Prmt5抑制剂及其制备方法
CN122341615A (zh) * 2023-12-01 2026-07-03 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用
CN121398850A (zh) * 2024-01-26 2026-01-23 上海湃隆生物科技有限公司 包含prmt5抑制剂和egfr抑制剂的药物组合物
AU2025211895A1 (en) * 2024-01-26 2026-08-06 Apeiron Therapeutics (Hong Kong) Ltd. Pharmaceutical composition comprising prmt5 inhibitor and chemotherapeutic agent
WO2025176054A1 (zh) * 2024-02-20 2025-08-28 华润医药研究院(深圳)有限公司 三环杂环类化合物及其制备方法和医药用途
WO2025194059A1 (en) * 2024-03-15 2025-09-18 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with taxane anticancer agent
WO2025207705A1 (en) * 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
TW202606706A (zh) * 2024-04-05 2026-02-16 美商安進公司 使用mta協作的prmt5抑制劑的胃腸癌治療
WO2025250569A1 (en) * 2024-05-29 2025-12-04 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
WO2025265110A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3923950A1 (en) * 2019-02-13 2021-12-22 Les Laboratoires Servier SAS Combination therapies for use in treating cancer
MX2022010011A (es) * 2020-02-12 2022-10-18 Amgen Inc Inhibidores de prmt5 novedosos.
LT4263545T (lt) * 2020-12-16 2026-07-27 Amgen Inc. Prmt5 inhibitoriai

Also Published As

Publication number Publication date
US20250228861A1 (en) 2025-07-17
TW202345844A (zh) 2023-12-01
CA3255376A1 (en) 2023-10-12
ZA202407596B (en) 2025-06-25
AU2023249277A1 (en) 2024-10-17
JP2025511399A (ja) 2025-04-15
WO2023196545A1 (en) 2023-10-12
CN119317435A (zh) 2025-01-14
KR20240169712A (ko) 2024-12-03
CL2024003040A1 (es) 2025-02-21
IL315996A (en) 2024-11-01
EP4504199A1 (en) 2025-02-12
MX2024012431A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
CL2024003040A1 (es) Tratamientos del cáncer con inhibidores de prmt5 cooperativos con mta
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2025007373A (es) Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
MX2019013862A (es) Terapia de combinacion.
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
MX2023002332A (es) Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2024000674A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2025001965A (es) Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
MX2023014778A (es) Terapia de combinacion de radioinmunoconjugados e inhibidores de puntos de control.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2024004171A (es) Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer.
JOP20220073A1 (ar) استخدام مثبطات fgfr في السرطانات المعدلة جينيا بـ fgfr لتحسين استجابة المريض لتحصين مثبطات نقطة الفحص في أوضاع علاجية تتابعية
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.